Central Texas Veterans' Healthcare System
Olin E. Teague Veterans’ Medical Center
Initial Study Results from Ongoing EOScu Clinical Trial at the
Olin E. Teague Veterans’ Medical Center
%
Mean bioburden on copper surface was 81% lower at hour 30 than non-copper

Copper-impregnated tray tables had lower microbial burden than standard material

Bioburden difference between surfaces was statistically significant beyond 24 hours
Evaluating the Clinical Benefits of EOScu
In June 2016, EOS Surfaces officially entered into a CRADA (Cooperative Research and Development Agreement) with the Central Texas Veterans Health Care System in Temple, TX. A CRADA is a legal “contract” that allows the Department of Veterans Affairs (VA) to enter into a relationship with a private company in the interest of studying the potential impact of technologies on the care of veterans while not violating the rules that prohibit financial investments or formal endorsements. The study will further test the efficacy of EOS Surfaces’ copper-infused hard surface, EOScu, in reducing both the bioburden as well as its impact on the hospital acquired infection (HAI) rates in a healthcare setting.

The Trial
The facility will outfit all 120 patient rooms with EOScu Preventive|Biocidal Surfaces™ (Cupron Enhanced EOS). The Olin E. Teague VAMC installation will include all countertops, over-the-bed tables and bed rails in the facility, providing additional protection against bacterial infection above and beyond existing infection control protocols.
Recent studies demonstrate that surfaces play a large role in the transmission of disease-causing pathogens by serving as reservoirs. Bioburden, the amount of microbiological or organic material on an object prior to decontamination or sterilization, has been demonstrated to correlate with infection rates. The earliest phase of the study aims to confirm how EOScu decreases the bacteria on the surface between routine sanitation efforts. The trial will also include a longer term study to verify EOScu‘s to reduce HAIs and costs associated with readmissions.
The Location
The trial was launched in October 2016 at the Olin E. Teague Veterans’ Medical Center (VAMC), part of the Central Texas Veterans’ Healthcare System, located in Temple, Texas.
As one of the largest healthcare systems in the US, the Veterans Health Administration (VHA) provides essential care to more than 8.7 million veterans in 300 VA hospitals, as well as 827 community-based outpatient clinics. Veterans are particularly vulnerable to HAIs and as a result, VA has made infection prevention a top priority. Its Health Services Research & Development Service (HSR&D) has conducted several studies focused on detecting and preventing HAIs.

The company’s second, large-scale trial includes:
- EOScu Preventive|Biocidal SurfacesTM installed on most horizontal surfaces in the 120 patient rooms as well as common areas such as nurses’ stations.
- Each patient room will also have EOScu overbed tables, bed rail kits, side tables, and sinks/vanities.
- Multiple publications, including short-term bioburden research and longer-term research on the impact of EOScu Preventive|Biocidal SurfacesTM on HAI rates

See the EOScu difference
Request a sample today